Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AssigneeMaxim Pharmaceuticals, Inc.
InventorsKristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
Claims13
A method for treating a subject suffering from radiation injury comprising:
- identifying a subject presenting the symptoms of radiation injury caused or exacerbated by the release of reactive oxygen metabolites (“ROMs”) from phagocytic cells resulting in ROM-mediated oxidative damage;
- and
- administering a compound effective to inhibit the production or release of the ROMs, wherein the ROM production or release compound is selected from the group consisting of histamine, and histamine dihydrochloride.
A drug administration method comprising:
- identifying a subject present the symptoms of radiation injury caused or or exacerbated by the release of a reactive oxygen metabolites (“ROMs”) from phagocytic cells resulting in ROM-mediated oxidative damage;
- loading an infusion device with a compound effective to inhibit the production or release of ROMs;
- and
- administering a compound effective to inhibit the production or release of the ROMs, wherein the ROM production or release compound is selected from the group consisting of histamine, histamine phosphate, and histamine dihydrochloride.
Dependencies are inferred from the claim text.